Licensed rights and other intangible assets

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Licensed rights and other intangible assets

5. Licensed rights and other intangible assets

The following provides information about our license rights and other intangible assets, net as of September 30, 2023 and December 31, 2022 (in thousands):

	September 30, 2023						December 31, 2022
	Gross Carrrying Amount		Accumulated Amortization		Net		Gross Carrrying Amount		Accumulated Amortization		Net
Intangible assets subject to amortization:
Hormone therapy drug patents	$	6,224	$	1,824	$	4,400	$	6,225	$	1,598	$	4,627
Hormone therapy drug patents applied and pending approval		1,936		—		1,936		1,995		—		1,995
Intangible assets subject to amortization		8,160		1,824		6,336		8,220		1,598		6,622
Intangible assets not subject to amortization:
Trademarks/trade name rights		321		—		321		321		—		321
License rights and other intangible assets, net	$	8,481	$	1,824	$	6,657	$	8,541	$	1,598	$	6,943

We recorded, in continuing operations, amortization expense related to patents of $0.1 million and $0.1 million for the three months ended September 30, 2023 and 2022, respectively, and amortization expense related to patents of $0.2 million and $0.4 million for the nine months ended September 30, 2023 and 2022, respectively.

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

Year ending December 31,
2023	$	110
2024		439
2025		438
2026		438
2027		438
Thereafter		2,537
Total	$	4,400